Only Participating Clinical Site in the Northeast United States
HOPEWELL, N.J., July 8, 2024
/PRNewswire/ -- Capital Health Cancer Center has announced that it
has joined TVAX Biomedical, Inc.'s clinical trial to study a
potential novel therapy for glioblastoma (GBM), the most common
type of malignant brain cancer. Capital Health Cancer Center is one
of five clinical sites open in the United
States and currently the only East Coast location north of
Florida to offer access to the
TVAX trial.
"Our participation in clinical trials is critical to Capital
Health's focus on providing the best and most personalized care
possible for our patients," said Dr. Navid Redjal, director of
Neurosurgical Oncology at Capital Health. "Thanks to the efforts of
our amazing clinical and research teams, we're excited to offer
this groundbreaking trial to our patients and contribute data to a
study that could lead to an exciting new therapy for treating
GBM."
There have been many trials over the past 20 years seeking to
use the power of the immune system to attack GBM. None to date has
proven effective. The investigational approach proposed by the TVAX
protocol utilizes a patient's own tumor cells to create a vaccine,
which then is given to the patient to generate a specific immune
response to their tumor. The laboratory collects, activates and
expands these anti-tumor immune cells, which may lead to a more
robust immune response when given back to the patient. The goal of
this study is to evaluate whether or not this approach will
overcome the natural tumor immune suppression of GBM and allow the
immune system to kill remaining tumor cells.
"We're excited to be part of studies like the TVAX trial and
offer patients new possibilities for treatment of glioblastoma,"
said Dr. Michael Salacz, director of Medical Neuro-Oncology at
Capital Health. "This is a true personalized treatment approach
that uses a patient's own tumor to unlock the power of their immune
system to kill any remaining cancer cells. Our participation in the
study could lead to better outcomes for patients and their families
fighting brain tumors like glioblastoma in our region and
beyond."
"TVAX Biomedical is very pleased to include Capital Health and
the expertise of Drs. Navid Redjal and Michael Salacz and their
entire staff in this study. We hope this late-stage clinical study
will significantly improve clinical outcomes for these patients
with so few options," said Dr. Wayne
Carter, CEO of TVAX Biomedical.
The TVAX clinical trial at Capital Health Cancer Center is open
to adults from age 18 to 80 with a new diagnosis of glioblastoma
with methylguanine methyltransferase (MGMT) that is active or
"unmethylated." Because collecting enough cells to create the
vaccine is the first step of this immune treatment, patients will
need to be able to have surgery at Capital Health. Trial
screening is required to determine if candidates meet the full
criteria for participation in any clinical trial.
To learn more about this and other ongoing trials available
at Capital Health's Center for Neuro-Oncology, please call
609-394-4130.
About TVAX Biomedical, Inc.
TVAX Biomedical, Inc., based in Lenexa, Kansas, is developing an
investigational new approach to cancer treatment that could lead to
improved clinical outcomes, low toxicity, and the potential for
fundamentally changing the way cancer is treated. The TVAX
immunotherapy trial uses both cancer vaccine pretreatment
to generate cancer-specific T cells and activated "killer" T
cell treatment. In addition to Capital Health, other TVAX sites
that are part of this study are located in Los Angeles, California, Orlando, Florida; and Kansas City, Kansas.
About Capital Health
Capital Health is the Central New
Jersey/Lower Bucks County region's leader in providing
progressive, quality patient care. Comprising two hospitals
(Capital Health Regional Medical Center in Trenton and Capital Health Medical Center –
Hopewell), Bordentown and Hamilton outpatient facilities, and various
primary and specialty care practices across the region, Capital
Health is a dynamic health care resource accredited by DNV –
Healthcare, and a five-time Magnet-designated health system for
nursing excellence.
The Center for Neuro-Oncology, part of Capital Institute for
Neurosciences and Capital Health Cancer Center, is a referral
center for the diagnosis and treatment of cancer involving the
brain and spine. The Center is housed in state-of-the-art
facilities where patients have access to an experienced and caring
team of physicians, nurses and staff who work closely with
referring physicians to facilitate rapid and thorough evaluations
and recommendations for patients and their families. In addition to
providing advanced neuro-oncologic and neuroscience care, the
Center participates in clinical trials to develop better ways to
fight cancer. To learn more,
visit capitalhealth.org/neurooncology.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/capital-health-partnering-with-tvax-biomedical-to-offer-brain-cancer-immunotherapy-trial-302189274.html
SOURCE CAPITAL HEALTH